Macitentan (macitentan) listing status and price information

Macitentan (macitentan) is an endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH), originally developed by Actelion Pharmaceuticals Ltd.. This drug effectively improves pulmonary vascular resistance and delays disease progression by blocking the binding of endothelin-1 to its receptors. It has become an important choice for the treatment of pulmonary arterial hypertension. Currently, macitentan has been approved for marketing in many countries and regions around the world, including China, the United States and the European Union, and has been included in my country's medical insurance directory, providing patients with more medication options and financial support.

Judging from the market situation, macitentan was first approved in the United States on October 18, 2013 (trade name: Opsumit), and was subsequently approved in the EU on December 20, 2013. In China, the drug was released on 2020year9month10 was officially approved for launch on the 1st, with the trade name Aoposu", filling some gaps in the domestic field of pulmonary arterial hypertension treatment. In addition to the original drugs, countries such as Laos and India have also approved multiple generic versions for marketing, including LuciMaciLuciMaci from Laos and MSN Pharmaceuticals from IndiaMSN Macitent and India's Cipla Pharmaceutical's Opsutan, etc., provide patients with more accessible choices.

In terms of price, the domestic market price of the original drug macitentan is about RMB 6,000 per box (10mg*30tablets). Thanks to the coverage of medical insurance policies, patients who meet the reimbursement conditions can enjoy a certain percentage of medical insurance reimbursement. It is recommended to consult the local hospital or pharmacy for specific reimbursement ratios and procedures. At the same time, the price of overseas generic drugs is relatively low. The price range of generic versions produced in Laos and India ranges from RMB 300 to more than 1,000 yuan, which is only one-fifth to one-sixth of the price of original drugs. It should be noted that although these generic drugs have price advantages, their drug ingredients are basically the same as the original drugs, and their quality has been approved by relevant regulatory authorities.

Macitentan has clear indications and is specifically used to treat pulmonary arterial hypertension (WHOGroup 1). It can effectively delay disease progression, including reducing the risk of death, reducing the need for hospitalization, and improving clinical symptoms. The standard recommended dose is 10mg taken orally once a day, which is easy to use and is not affected by eating. It is worth noting that this drug needs to be initiated and monitored by a doctor with experience in the treatment of pulmonary arterial hypertension to ensure the safety and effectiveness of the drug.

In general, macitentan is an important drug in the treatment of pulmonary arterial hypertension. Its domestic launch and inclusion in medical insurance have significantly improved the accessibility of the drug to patients. The diverse selection of original drugs and generic drugs provides treatment opportunities for patients with different economic conditions. However, when considering using overseas generic drugs, patients still need to carefully choose formal drug purchase channels and conduct treatment under the guidance of professional doctors. With the continuous improvement of medical insurance policies and the optimization of the drug supply system, it is believed that more patients with pulmonary hypertension will be able to receive timely and effective treatment.

Reference materials:https://www.opsumit.com/